<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705989</url>
  </required_header>
  <id_info>
    <org_study_id>IM014-001</org_study_id>
    <nct_id>NCT02705989</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD), and Non-Randomized, Bioavailability(BA) Study of BMS-986195 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics,
      and pharmacodynamics following single and multiple ascending oral doses of BMS-986195 in
      healthy subjects, and to assess the relative bioavailability of two formulations of
      BMS-986195 with or without food.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2016</start_date>
  <completion_date type="Actual">August 16, 2017</completion_date>
  <primary_completion_date type="Actual">August 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single oral dose of BMS-986195 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests</measure>
    <time_frame>Up to 8 days during and after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of multiple oral doses of BMS-986195 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests</measure>
    <time_frame>Up to 21 days during and after last dose</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">439</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending dose of BMS-986195 or Placebo matching BMS-986195</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese-Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relative Bioavailability with Food Effects (Open Label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986195</intervention_name>
    <description>Specified dose on specified day</description>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Japanese-Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Relative Bioavailability with Food Effects (Open Label)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified day</description>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Japanese-Multiple Ascending Dose(MAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Body Mass Index(BMI) of 18 to 32 kilograms/meter^2

          -  Healthy male and female, first generation Japanese with confirmed paternal and
             maternal Japanese ancestry, 18-55 years old, whose residency outside of Japan does not
             exceed 10 years with a BMI of 18-30 kilograms/meter^2 inclusive.

          -  Women must not be pregnant or breastfeeding

          -  Women of Childbearing Potential (WOCBP) must agree to follow instructions for
             method(s) of contraception for the duration of treatment with study drug plus 14 days
             or longer if required.

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for the duration of treatment with study drug plus 14 days
             or longer if required.

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Known or suspected autoimmune disorder, including but not limited to rheumatoid
             arthritis, fibromyalgia, systemic lupus erythematosis, polymyalgia rheumatica, giant
             cell arteritis, Behcet's disease, dermatomyositis, multiple sclerosis, moderate to
             severe asthma, any autoimmune vasculitis, autoimmune hepatitis, or any other active
             autoimmune disease for which a subject requires medical follow-up or medical treatment

          -  Any history of known or suspected congenital or acquired immunodeficiency state or
             condition that would compromise the subject's immune status (example: history of
             splenectomy)

          -  Presence of any factors that would predispose the subject to develop infection e.g.,
             rectal fissures, poor dentition, open skin lesions, and presence of preexisting skin
             conditions that increase risks for injection site complications e.g. Behcet's Disease,
             Psoriasis, pustular dermatoses

          -  Any history or risk for tuberculosis (TB)

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

